Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3908
Revised: April 26, 2024
Accepted: May 22, 2024
Published online: July 6, 2024
Processing time: 110 Days and 21.7 Hours
In the past decade, the evolution of themes in the field of osteoporotic fractures has changed from epidemiology and prediction of long-term morbidity, risk assessment of osteoporotic fractures, and zoledronic acid and denosumab in the treatment of osteoporosis to treatment guidelines for osteoporosis and the side effects caused by anti-osteoporotic drugs.
To understand the trends and hotspots in osteoporotic fracture research.
Original articles were retrieved between January 1, 2010, and December 31, 2019, from the Web of Science Core Collection database. CiteSpace software facilitated the analysis and visualization of scientific productivity and emerging trends.
Nine studies were identified using bibliometric indices, including citation, centrality, and sigma value, which might indicate a growing trend. Through clustering, we identified six major hot subtopics. Using burst analysis, top-5 references with the strongest bursting strength after 2017 were identified, indicating a future hotspot in this field.
Current hot subtopics in osteoporotic fracture research include atypical femoral fractures, androgen deprivation therapy, denosumab discontinuation, hip fractures, trabecular bone score (TBS), and bone phenotype. Management and prevention of secondary fractures in patients with osteoporotic fractures, TBSs, and long-term administration strategy for zoledronic acid are expected to become research hotspots.
Core Tip: The evolution process of the research focus in the field of osteoporosis fractures in the past decade has changed from epidemiological statistics and long-term incidence prediction to osteoporosis fracture risk assessment and significant effects of zoledronic acid and denosumab on reducing fracture risk in osteoporosis treatment to the proposal of osteoporosis treatment guidelines and the adverse reactions caused by anti-osteoporosis drugs such as zoledronic acid. Current hot topics in the treatment of osteoporosis fractures include atypical femoral fractures, osteoporosis fractures caused by androgen deprivation, increased fracture risk due to denosumab discontinuation, hip fractures, trabecular bone scores, and genes related to bone density or osteoporosis fracture phenotypes.